Device Trial Radar · NCT05668377
Automated Diagnostic Performance of Smartwatch ECG for Arrhythmia Detection Using the PulseAI Neural Network.
Last checked: Nov 19, 2026Latest source record: Dec 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
300
Planned (sponsor's estimate)
Start
Jan 1, 2023
Primary completion
Jan 1, 2024
Study completion Jan 1, 2024
Sponsor
- Lead sponsor
- PulseAI LtdNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Beacon Hospital Research Institute, Dublin, Ireland
- First posted
- Dec 29, 2022
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is to evaluate the performance of the PulseAI neural network technology at interpreting ECG data recorded using a single-lead Smartwatch (Apple Watch).
Conditions
- Arrhythmias, Cardiac
Interventions
PulseAI ECG PlatformDevice
Cloud-based AI-enabled ECG analysis platform
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the performance of arrhythmia detection.Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beacon Hospital Research Institute
Dublin, Ireland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.